Product Details
1/UN
$1,268.70
In Stock1/EA
$ *.**
In StockAdditional Information
| Product Name | Nulojix 250 mg Vial |
| Application | Prevention of Kidney Transplant Rejection |
| Active Ingredient | Belatacept |
| Mechanism of Action | Selective T-cell co-stimulation blocker that inhibits CD80/CD86 interaction to prevent T-cell activation |
| Dosage Form | Lyophilized Powder for Intravenous Infusion |
| Strength | 250 mg per vial |
| Administration Route | Intravenous (IV) Infusion |
| Dosing Schedule | Initial intensive dosing followed by maintenance every 4 weeks |
| Reconstitution Requirements | Requires dilution with sterile water for injection before IV administration |
| Common Side Effects | Anemia, diarrhea, urinary tract infections, peripheral edema, hypertension |
| Contraindications | EBV-seronegative patients due to risk of post-transplant lymphoproliferative disorder (PTLD) |
| Packaging | Single-use vial |
| Uses | Prevention of acute rejection in kidney transplant recipients as part of an immunosuppressive regimen |
Description
Nulojix 250 mg Vial is an immunosuppressive agent used for the prevention of organ rejection in adult patients receiving a kidney transplant. It contains belatacept, a selective T-cell co-stimulation blocker that helps suppress the immune system’s response to the transplanted organ. It is administered in combination with other immunosuppressive therapies, including corticosteroids and mycophenolate mofetil, to achieve effective graft protection.
The active ingredient, belatacept, functions by binding to CD80 and CD86 receptors on antigen-presenting cells, thereby preventing the activation of T-cells. This mechanism reduces the immune-mediated attack on the transplanted kidney, lowering the risk of acute rejection.
This medication is specifically indicated for Epstein-Barr virus (EBV)-seropositive kidney transplant recipients due to an increased risk of post-transplant lymphoproliferative disorder (PTLD) in EBV-negative patients. It is used under strict medical supervision to balance immunosuppression while reducing the risk of infection and malignancy.
Frequently Asked Questions (FAQs)
The cost of NULOJIX(BELATACEPT) VL+SYR EA is $$0.00
NULOJIX(BELATACEPT) VL+SYR EA is manufactured by BMS.
You can purchase NULOJIX(BELATACEPT) VL+SYR EA on our website at https://supplies.pipelinemedical.com/product/detail/nulojixbelatacept-vl-syr-ea-665791